Lyell Immunopharma, Inc.
LYEL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 87.5% | 14.3% | -36.4% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $28 | $35 | $43 | $49 |
| G&A Expenses | $11 | $10 | $14 | $15 |
| SG&A Expenses | $11 | $10 | $14 | $15 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$2 | $3 | -$0 | $138 |
| Operating Expenses | $37 | $47 | $57 | $201 |
| Operating Income | -$37 | -$47 | -$57 | -$201 |
| % Margin | -248,353.3% | -589,250% | -819,528.6% | -1,828,609.1% |
| Other Income/Exp. Net | -$2 | $4 | $5 | $9 |
| Pre-Tax Income | -$39 | -$43 | -$52 | -$192 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$39 | -$43 | -$52 | -$192 |
| % Margin | -258,973.3% | -533,550% | -745,642.9% | -1,744,863.6% |
| EPS | -2.13 | -2.89 | -0.18 | -0.72 |
| % Growth | 26.3% | -1,505.6% | 75% | – |
| EPS Diluted | -2.13 | -2.89 | -0.18 | -0.72 |
| Weighted Avg Shares Out | 18 | 15 | 15 | 13 |
| Weighted Avg Shares Out Dil | 18 | 15 | 15 | 13 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $3 | $4 | $5 |
| Interest Expense | – | $0 | $0 | $0 |
| Depreciation & Amortization | $3 | $3 | $3 | $5 |
| EBITDA | -$36 | -$43 | -$54 | -$58 |
| % Margin | -241,866.7% | -532,025% | -770,371.4% | -524,000% |